×
EULAR/ACR Criteria Identify SLE in Hospitalized Pericarditis Patients
https://www.medscape.com/viewarticle/922957

Dec 22nd, 2019 - NEW YORK (Reuters Health) - New European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria can be used to identify patients with systemic lupus erythematosus (SLE) in an unselected group of patients hospitalized for pericardial effusion (PE), new findings show. "Overall, in patients with pericardial effusion and positive ANA, the diagnosis of SLE cou...

Be proactive in fracture prevention
https://www.mdedge.com/rheumatology/article/214488/osteoporosis/be-proactive-fracture-prevention?channel=53
Elizabeth Shane, MD

Dec 18th, 2019 - Several studies published over the last few years have shown declining rates of diagnosis and treatment of osteoporosis in older adults. In part, this may be due to declining ability to diagnose osteoporosis because declining reimbursement for dual x-ray absorptiometry has made it less available to patients and doctors.

Osteoporotic fracture risk is undermanaged in older adults
https://www.mdedge.com/internalmedicine/article/214483/osteoporosis/osteoporotic-fracture-risk-undermanaged-older-adults?channel=290
Heidi Splete

Dec 18th, 2019 - Treatment of osteoporosis in older adults at increased risk for fractures declined from 2010 to 2014, based on a study of nearly 900,000 individuals. Courtesy University of Alabama at Birmingham Dr.

Well-tolerated topical capsaicin formulation reduces knee OA pain
https://www.mdedge.com/internalmedicine/article/214467/osteoarthritis/well-tolerated-topical-capsaicin-formulation-reduces?channel=290
Jeff Craven

Dec 18th, 2019 - ATLANTA – Use of high-concentration topical capsaicin was associated with reduced pain, a longer duration of clinical response, and was well tolerated in patients with knee osteoarthritis, compared with lower concentrations of capsaicin and placebo, according to recent research presented at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Tim Warneke While the.

Hydroxychloroquine prevents congenital heart block recurrence in anti-Ro pregnancies
https://www.mdedge.com/internalmedicine/article/214451/lupus-connective-tissue-diseases/hydroxychloroquine-prevents?channel=290
M. Alexander Otto

Dec 17th, 2019 - ATLANTA – Hydroxychloroquine (Plaquenil) 400 mg/day starting by pregnancy week 10 reduces recurrence of congenital heart block in infants born to women with anti-Ro antibodies, according to an open-label, prospective study presented at the annual meeting of the American College of Rheumatology. M.

ACR and EULAR release first classification criteria for IgG4-related disease
https://www.mdedge.com/internalmedicine/article/214448/lupus-connective-tissue-diseases/acr-and-eular-release-first?channel=290
Jeff Craven

Dec 17th, 2019 - The American College of Rheumatology and the European League Against Rheumatism have released the first classification criteria for IgG4-related disease. Although it was first recognized as a distinct disease in 2003, investigators have since learned that IgG4-related disease (IgG4-RD) is not particularly rare.

Three Quick Tips for Managing Osteoarthritis
https://www.medscape.com/viewarticle/922004

Dec 12th, 2019 - This transcript has been edited for clarity. Matthew F. Watto, MD: As usual, we're coming in hot. This is the Curbsiders. I am Dr Matthew Watto. Here are my two wonderful cohosts, Dr Stuart Brigham and Dr Paul Williams. Tonight we are going to be talking about osteoarthritis (OA). We had a wonderful interview with Dr Tuhina Neogi, the chair of rheumatology at Boston University School of Medicin...

VEDOSS study describes predictors of progression to systemic sclerosis
https://www.mdedge.com/dermatology/article/214179/lupus-connective-tissue-diseases/vedoss-study-describes-predictors?channel=39313
Jeff Craven

Dec 12th, 2019 - ATLANTA – Patients with Raynaud’s phenomenon and puffy fingers, disease-specific antibodies, and/or nailfold video capillaroscopy abnormalities were more likely to progress to systemic sclerosis within 5 years than were patients without those features, according to recent results from the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) study presented at the annual meeting of the American C.

Ixekizumab Curbs Disease Activity, Improves Quality of Life in Axial Spondyloarthritis
https://www.medscape.com/viewarticle/922454

Dec 11th, 2019 - NEW YORK (Reuters Health) - Treatment with the interleukin-17 inhibitor ixekizumab (Taltz, Lilly) significantly improves signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA), according to results of the COAST-X study. The results of the phase-3 randomized controlled trial were presented in November during a plenary session at the American College of Rheumatology (ACR) annua...

Tofacitinib improves disease activity in patients with polyarticular-course JIA
https://www.mdedge.com/fedprac/article/214064/pediatrics/tofacitinib-improves-disease-activity-patients-polyarticular?channel=285
Jeff Craven

Dec 11th, 2019 - ATLANTA – Treatment of polyarticular-course juvenile idiopathic arthritis with tofacitinib led to significantly fewer disease flares and greater improvement in disease activity than with placebo in a phase 3, multinational, randomized, double-blind, controlled withdrawal study presented at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Dr.

ADA2 is a potent new biomarker for macrophage activation syndrome
https://www.mdedge.com/fedprac/article/214103/pediatrics/ada2-potent-new-biomarker-macrophage-activation-syndrome?channel=285
Jeff Craven

Dec 11th, 2019 - ATLANTA – Adenosine deaminase 2 above the upper limit of normal is 86% sensitive and 94% specific for distinguishing macrophage activation syndrome from active systemic juvenile idiopathic arthritis, making it perhaps the most potent blood marker yet identified to differentiate the two, according to a report presented at the annual meeting of the American College of Rheumatology. Dr.

Repeat LTBI testing best in patients taking biologics with new risk factors
https://www.mdedge.com/fedprac/article/213923/rheumatoid-arthritis/repeat-ltbi-testing-best-patients-taking-biologics-new?channel=234
Jeff Craven

Dec 9th, 2019 - ATLANTA – Patients taking biologics who received latent tuberculosis testing on an annual basis were unlikely to convert from a negative QuantiFERON test to a positive result, which suggests that the test may be unnecessary for patients without new tuberculosis risk factors, according to research presented at the annual meeting of the American College of Rheumatology. In addition, nearly all of.

Perioperative antirheumatic drug use does not impact postsurgery infection rate in RA patients
https://www.mdedge.com/jcomjournal/article/213883/rheumatoid-arthritis/perioperative-antirheumatic-drug-use-does-not-impact?channel=302
Jeff Craven

Dec 9th, 2019 - ATLANTA – Patients with rheumatoid arthritis were more at risk of postoperative infection because of a high Charlson Comorbidity Index or longer surgery time than because of perioperative use of antirheumatic medications, according to a presentation at the annual meeting of the American College of Rheumatology. Jeff Craven/MDedge News Dr.

Updated gout guidelines: Don’t let kidney function dictate allopurinol dosing
https://www.mdedge.com/clinicianreviews/article/213863/gout/updated-gout-guidelines-dont-let-kidney-function-dictate?channel=53
M. Alexander Otto

Dec 9th, 2019 - ATLANTA – Soon-to-be-published gout guidelines from the American College of Rheumatology will recommend dosing allopurinol above 300 mg/day to get serum urate below 6 mg/dL, even in people with renal impairment. M.

Evidence grows for early axSpA treatment, uveitis flare prevention
https://www.mdedge.com/rheumatology/article/213740/ankylosing-spondylitis/evidence-grows-early-axspa-treatment-uveitis?channel=299
Denis Poddubnyy, MD

Dec 6th, 2019 - The findings from the C-axSpAnd study that Jonathan Kay, MD, and colleagues reported at the annual meeting of the American College of Rheumatology are not surprising. Earlier studies in patients with ankylosing spondylitis showed that short symptom duration is one of the best predictors of good treatment response to TNFi therapy.

Systemic Lupus Erythematosus Highlights From the 2019 ACR Annual Meeting
https://www.medscape.com/viewarticle/920781

Dec 5th, 2019 - New data relevant to the treatment of systemic lupus erythematosus (SLE) were presented at the 2019 annual meeting of the American College of Rheumatology in Atlanta. Dr Michelle Petri, who heads the Johns Hopkins Lupus Center, discusses key findings, including the results of two important clinical trials on the anti–interferon receptor blocker anifrolumab. TULIP 1, the first of the two phase 3...

Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitis
https://www.mdedge.com/internalmedicine/article/213422/ankylosing-spondylitis/upadacitinib-doubles-asas-40-response-vs?channel=53
Sharon Worcester

Dec 3rd, 2019 - ATLANTA – Upadacitinib (Rinvoq), a selective Janus kinase 1 (JAK1) inhibitor, significantly improved the signs and symptoms of active ankylosing spondylitis, compared with placebo, in the randomized, placebo-controlled, phase 2/3 SELECT-AXIS 1 study. Dr.

Live Zoster Vaccine Safe in People on TNF Inhibitors
https://www.medscape.com/viewarticle/921734

Nov 25th, 2019 - NEW YORK (Reuters Health) - Patients with rheumatic diseases who are on tumor-necrosis-factor inhibitor (TNFi) therapy can safely receive the live varicella zoster vaccine, without risking vaccine-related infection, a new study suggests. "Because patients with rheumatic diseases are at higher risk for reactivation of herpes zoster, also known as shingles, prevention of this painful condition is...

Tanezumab posts higher safety event rate than NSAIDs over 1 year in hip, knee OA
https://www.mdedge.com/rheumatology/article/213000/osteoarthritis/tanezumab-posts-higher-safety-event-rate-nsaids-over-1?channel=53
Jeff Craven

Nov 25th, 2019 - ATLANTA – Patients with moderate to severe osteoarthritis of the hip and knee who took the investigational anti-nerve growth factor monoclonal antibody tanezumab experienced a significantly higher rate of joint safety events than that of patients who received NSAIDs as part of a recent randomized, double-blind, active-controlled, phase 3 study. Jeff Craven/MDedge News Dr.

Large population-based study underscores link between gout, CVD event risk
https://www.mdedge.com/cardiology/article/212979/gout/large-population-based-study-underscores-link-between-gout-cvd-event?channel=39313
Sharon Worcester

Nov 23rd, 2019 - ATLANTA – Gout is associated with an increased risk of both fatal and nonfatal cardiovascular disease events, according to a large population-based health data linkage study in New Zealand. Sharon Worcester/MDedge News Dr.